Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 6:08 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 6:08 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.
PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance
by Zacks Equity Research
PerkinElmer (PKI) posted stellar third-quarter numbers from strong performance in particularly the Diagnostics segment.
Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated
by Zacks Equity Research
Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.
Align Technology (ALGN) Gains on InvisAlign, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet
by Zacks Equity Research
DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.
Omnicell's Higher Investments Drive Costs, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.
STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up
by Zacks Equity Research
STERIS (STE) witnessed year-over-year decline in Q2 revenues due to softness in Healthcare Products and the Healthcare Specialty Services segments.
Integra Gains on Global Growth, Hurricanes Hamper Business
by Zacks Equity Research
Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.
Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid
by Zacks Equity Research
Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.
Wright Medical Group (WMGI) Q3 Earnings In Line, Sales Miss
by Zacks Equity Research
Wright Medical (WMGI) posted loss as estimated in the third quarter on lower-than-expected sales.
Zimmer Biomet's (ZBH) Q3 Earnings Lag Estimates, View Down
by Zacks Equity Research
Zimmer Biomet's (ZBH) declining revenue performance within most of the core segments, along with a rise in cost of products sold resulted in bottom line pressure in the third quarter.
Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View
by Zacks Equity Research
Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.
IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
Ecolab (ECL) Beats Earnings & Revenues in Q3, Cuts 2017 View
by Zacks Equity Research
Despite reporting solid third-quarter results, Ecolab (ECL) slashed its full-year earnings guidance, thanks to the hurricanes and the divestiture of the Equipment Care business segment.
Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.
Quality Systems (QSII) Beats on Earnings & Revenues in Q2
by Zacks Equity Research
Quality Systems' (QSII) solid total software, hardware revenues drove second-quarter earnings. A solid recurring revenue base is a key catalyst for the quarters to come.
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.
Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues
by Zacks Equity Research
Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.
Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales
by Zacks Equity Research
An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.
Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on its Roto-Rooter business in Q3
ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines
by Zacks Equity Research
ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.
Stryker (SYK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Stryker (SYK) posted strong numbers in the third quarter owing to higher revenues.
Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y
by Zacks Equity Research
Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.